Activation of Rho GTPases in Smith–Lemli–Opitz syndrome: pathophysiological and clinical implications
Open Access
- 12 January 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 19 (7) , 1347-1357
- https://doi.org/10.1093/hmg/ddq011
Abstract
Smith–Lemli–Opitz syndrome (SLOS) is a malformation syndrome with neurocognitive deficits due to mutations of DHCR7 that impair the reduction of 7-dehydrocholesterol to cholesterol. To investigate the pathological processes underlying the neurocognitive deficits, we compared protein expression in Dhcr7+/+ and Dhcr7Δ3-5/Δ3-5 brain tissue. One of the proteins identified was cofilin-1, an actin depolymerizing factor which regulates neuronal dendrite and axon formation. Differential expression of cofilin-1 was due to increased phosphorylation. Phosphorylation of cofilin-1 is regulated by Rho GTPases through Rho-Rock-Limk-Cofilin-1 and Rac/Cdc42-Pak-Limk-Cofilin-1 pathways. Pull-down assays were used to demonstrate increased activation of RhoA, Rac1 and Cdc42 in Dhcr7Δ3-5/Δ3-5 brains. Consistent with increased activation of these Rho GTPases, we observed increased phosphorylation of both Limk and Pak in mutant brain tissue. Altered Rho/Rac signaling impairs normal dendritic and axonal formation, and mutations in genes encoding regulators and effectors of the Rho GTPases underlie other human mental retardation syndromes. Thus, we hypothesized that aberrant activation of Rho/Rac could have functional consequences for dendrite and axonal growth. In vitro analysis of Dhcr7Δ3-5/Δ3-5 hippocampal neurons demonstrated both axonal and dendritic abnormalities. Developmental abnormalities of neuronal process formation may contribute to the neurocognitive deficits found in SLOS and may represent a potential target for therapeutic intervention.Keywords
This publication has 53 references indexed in Scilit:
- Myosin‐II negatively regulates minor process extension and the temporal development of neuronal polarityDevelopmental Neurobiology, 2009
- A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse modelProceedings of the National Academy of Sciences, 2008
- Characterization of placental cholesterol transport: ABCA1 is a potential target for in utero therapy of Smith-Lemli-Opitz syndromeHuman Molecular Genetics, 2008
- The use of the Dhcr7 knockout mouse to accurately determine the origin of fetal sterolsJournal of Lipid Research, 2006
- The near universal presence of autism spectrum disorders in children with Smith–Lemli–Opitz syndromeAmerican Journal of Medical Genetics Part A, 2006
- Cholesterol deficiency in a mouse model of Smith-Lemli-Opitz syndrome reveals increased mast cell responsivenessThe Journal of Experimental Medicine, 2006
- A method for reducing the time required to match protein sequences with tandem mass spectraRapid Communications in Mass Spectrometry, 2003
- Empirical Statistical Model To Estimate the Accuracy of Peptide Identifications Made by MS/MS and Database SearchAnalytical Chemistry, 2002
- Two novel mutations confirm FGD1 is responsible for the Aarskog syndromeEuropean Journal of Human Genetics, 2000
- LIM–kinase deleted in Williams syndromeNature Genetics, 1996